Walleye Capital
FHTX icon

Walleye Capital’s Foghorn Therapeutics FHTX Stock Holding History

Walleye Capital’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34,445
Closed -$165K – 4867
2026
Q1 		$165K Sell
34,445
-46,903
-58% -$257K ﹤0.01% 3446
2025
Q4 		$439K Buy
81,348
+47,040
+137% +$213K ﹤0.01% 3033
2025
Q3 		$168K Hold
34,308
– – ﹤0.01% 3426
2025
Q2 		$161K Buy
34,308
+1,469
+4% +$6.14K ﹤0.01% 3518
2025
Q1 		$120K Sell
32,839
-1,209
-4% -$5.51K ﹤0.01% 3542
2024
Q4 		$161K Sell
34,048
-10,879
-24% -$79.3K ﹤0.01% 3890
2024
Q3 		$418K Buy
44,927
+27,782
+162% +$201K ﹤0.01% 3465
2024
Q2 		$98.6K Buy
+17,145
New +$102K ﹤0.01% 4725

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Walleye Capital's FHTX Position: Q2 2026 in Review

Walleye Capital sold out of Foghorn Therapeutics (FHTX) in Q2 2026, closing a stake of 34,445 shares — an estimated $165K sold.

Walleye Capital first reported a position in FHTX in Q2 2024 and held it in 8 quarters. The position peaked at $439K in Q4 2025. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Walleye Capital reported no remaining Foghorn Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 34,445 Foghorn Therapeutics shares in Q2 2026, an estimated $165K.
  • Walleye Capital first reported a position in Foghorn Therapeutics in Q2 2024 and held it in 8 quarters.
  • Walleye Capital's Foghorn Therapeutics position peaked at $439K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.